ABBV · Healthcare

AbbVie Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-07

• Licensing / Collaboration DealsImportance 50 · Surprise 42
  AbbVie agreed to a global licensing deal with Nxera Pharma for an oral EP4 receptor agonist targeting inflammatory bowel disease, with payments and other deal value of up to US$1.37 billion. AbbVie receives worldwide…
• Drug Pricing and Tariff ReliefImportance 40 · Surprise 42
  A report says the Inflation Reduction Act (IRA) could create a pricing headwind for AbbVie’s psychiatry drug Vraylar in 2027. It says continued growth from Skyrizi and Rinvoq will be important to offset the anticipated…

News · 2026-11-06

• Licensing / Collaboration DealsImportance 52 · Surprise 42
  Japan-based Nxera Pharma signed an exclusive global licensing agreement with AbbVie for its EP4 agonist program, including candidate NXE0033744 for inflammatory bowel disease. AbbVie will pay $100 million upfront, and…
• Regulatory RiskImportance 44 · Surprise 42
  A government-set price for AbbVie’s drug Vraylar is scheduled to take effect in 2027. The report does not identify the government or disclose the price or estimated financial impact. It notes that Vraylar sales are…
• Revenue Performance and MixImportance 38 · Surprise 24
  Skyrizi and Rinvoq together account for nearly half of AbbVie’s total sales, according to Trefis. The two immunology treatments are growing significantly faster than AbbVie overall and are offsetting declines in Humira…
• Immunology Product Demand and ExpansionImportance 38 · Surprise 24
  Skyrizi and Rinvoq together account for nearly half of AbbVie’s total sales and are growing significantly faster than the company overall. Their growth is offsetting declines in older drugs, including Humira and…

News · 2026-11-05

• Licensing / Collaboration DealsImportance 52 · Surprise 42
  AbbVie entered a global licensing agreement with Nxera Pharma for NXE0033744, an investigational oral EP4 receptor agonist for inflammatory bowel disease. AbbVie will pay $100 million upfront, with Nxera eligible for…

News · 2026-11-04

• Licensing / Collaboration DealsImportance 45 · Surprise 42
  AbbVie obtained exclusive worldwide rights to develop and commercialize Nxera Pharma’s NXE0033744 EP4 receptor agonist program for inflammatory bowel disease. The agreement provides for a $100 million upfront cash…

10-Q · 2026-11-03

• Drug Pricing and Tariff ReliefImportance 66 · Surprise 42
  In January 2026, AbbVie announced a voluntary agreement with the U.S. government to advance access and affordability while protecting investment in U.S. pharmaceutical innovation. AbbVie will provide low prices in…
• Outstanding IndebtednessImportance 64 · Surprise 42
  AbbVie issued $18.0 billion aggregate principal of unsecured senior notes during the nine months ended September 30, 2026, and repaid $2.0 billion of a 364-day term loan and $2.0 billion of 3.20% senior notes. The…
• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  AbbVie’s investing cash flows included $10.6 billion of net cash payments for business acquisitions, primarily the Apogee Therapeutics acquisition, during the nine months ended September 30, 2026. The period also…
• Immunology Product Demand and ExpansionImportance 59 · Surprise 48
  Skyrizi net revenues increased 23% in the third quarter and 25% in the first nine months of 2026, driven by continued strong market share uptake and market growth across indications. Rinvoq net revenues increased 24%…
• Income Tax Rate ChangesImportance 57 · Surprise 64
  AbbVie’s effective tax rate was 13% for the third quarter and 16% for the first nine months of 2026, compared with 74% and 39%, respectively, in 2025. The decreases primarily reflected a reduced impact from…
• Revenue Performance and MixImportance 54 · Surprise 40
  Worldwide net revenues for the nine months ended September 30, 2026 were $49.396 billion, up 10.9% reported and 10.1% at constant currency; U.S. revenue rose 9.9% to $37.163 billion and international revenue rose 14.0%…
• Gross Margin DriversImportance 54 · Surprise 40
  Gross margin was $13.119 billion for the three months and $36.602 billion for the nine months ended September 30, 2026, compared with $10.472 billion and $30.890 billion, respectively, in 2025. Gross margin as a…
• Operating Expense TrendsImportance 54 · Surprise 40
  SG&A expense was $4.087 billion for the third quarter and $11.297 billion for the first nine months of 2026, versus $3.569 billion and $10.115 billion in the corresponding 2025 periods. SG&A as a percentage of revenue…
• Regulatory RiskImportance 53 · Surprise 60
  The Inflation Reduction Act of 2022 has and will continue to have a significant impact on AbbVie’s business. In January 2026, CMS selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts…
• Oncology Market PositionImportance 51 · Surprise 64
  Venclexta net revenues increased 11% in the third quarter and 10% in the first nine months of 2026, primarily driven by increased demand. Elahere grew 31% and 23%, respectively, on increased demand, while Epkinly net…
• Cash Flow and Capital AllocationImportance 49 · Surprise 32
  Operating cash flow for the first nine months of 2026 was $14.871 billion, up from $13.812 billion in 2025, reflecting higher operating results and lower litigation payments, partly offset by working-capital timing and…
• Neuroscience Market GrowthImportance 46 · Surprise 56
  Vraylar net revenues increased 14% in the third quarter and 17% in the first nine months, reflecting market share uptake, market growth and favorable pricing. Botox Therapeutic increased 10% and 12%, respectively, with…
• Other Non-Operating ExpensesImportance 43 · Surprise 32
  Changes in fair value of contingent consideration liabilities generated $4.7 billion of expense for the nine months ended September 30, 2026, compared with $5.1 billion in the same 2025 period. The 2026 change…
• Aesthetic Care Demand TrendsImportance 42 · Surprise 40
  Botox Cosmetic net revenues increased 4% in the third quarter and 8% in the first nine months, with growth driven primarily by increased consumer demand in certain international markets. Juvederm Collection declined…
• U.S. Manufacturing InvestmentImportance 40 · Surprise 42
  In 2026, AbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina, integrating advanced manufacturing and laboratory technologies with artificial intelligence. The campus is…
• Manufacturing Capacity ExpansionImportance 34 · Surprise 42
  AbbVie announced a pharmaceutical manufacturing campus in North Carolina that will use advanced manufacturing and laboratory technologies, including artificial intelligence, to support production of immunology,…
• Distribution ChannelsImportance 6 · Surprise 6
  AbbVie sells products worldwide through wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers, using company-owned distribution centers and public…

News · 2026-11-03

• Litigation and Legal RiskImportance 47 · Surprise 60
  On November 3, 2026, AbbVie won a court case shielding Botox from Medicare price negotiations. The ruling concerns the U.S. Medicare drug-price negotiation program and prevents Botox from being subjected to those…
• Guidance / OutlookImportance 43 · Surprise 60
  A November 3, 2026 report said AbbVie raised its guidance following its third-quarter results. The report does not provide the revised guidance figures, the prior outlook, or the timeframe covered. It also cites growth…
• Licensing / Collaboration DealsImportance 38 · Surprise 24
  AbbVie has a licensing agreement with Brise Pharmaceuticals covering two early-stage migraine drug programs, with payments of up to $757 million. The deal was originally forged in 2024; Brise will lead discovery, while…
• Revenue Performance and MixImportance 37 · Surprise 6
  AbbVie reported 2026 net revenues of $17.4 billion, significantly higher than the prior year. Net income was $4.22 billion, and diluted EPS was $2.37. Growth was driven by Skyrizi and Rinvoq, which offset Humira's…

News · 2026-11-02

• SKYRIZI Crohn’s Disease ProgressImportance 59 · Surprise 82
  AbbVie’s experimental ABBV-466, a combination of SKYRIZI and trosunilimab, showed positive Phase 2 results in Crohn’s disease. The combination nearly doubled the remission rate achieved by SKYRIZI alone, according to…
• Operating Income and MarginsImportance 56 · Surprise 46
  AbbVie’s third-quarter 2026 operating margin was reported at 36%, compared with 12.1% in the same quarter of 2025. The 23.9-percentage-point year-over-year increase is a significant margin change. The report also cited…
• Guidance / OutlookImportance 51 · Surprise 60
  AbbVie raised its 2026 revenue outlook by $200 million to approximately $67.8 billion. The company set adjusted EPS guidance at $13.95–$13.99 per share, with a midpoint of $13.97. Fourth-quarter 2026 revenue was…
• Immunology and Neuroscience DemandImportance 36 · Surprise 40
  AbbVie reported broad commercial momentum across its immunology and neuroscience portfolios in the third quarter. SKYRIZI, RINVOQ, and VRAYLAR each delivered double-digit revenue increases, and management said nine key…
• QULIPTA Migraine Trial ResultsImportance 34 · Surprise 42
  AbbVie reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention, published in The Lancet Neurology. QULIPTA showed superior migraine-prevention efficacy compared with topiramate, a widely used…
• Revenue Performance and MixImportance 29 · Surprise 22
  AbbVie’s third-quarter 2026 sales rose 10.3% year over year to $17.4 billion. Sales were slightly above the cited analyst estimate of $17.34 billion. The report attributed the quarter’s growth to immunology and…

News · 2026-10-31

• Revenue Performance and MixImportance 58 · Surprise 40
  AbbVie reported Q3 2026 revenue of $17.404 billion, up 10.3% year over year. SKYRIZI sales were $5.78 billion and RINVOQ sales were $2.71 billion. Those products offset a decline in HUMIRA sales.
• Guidance / OutlookImportance 57 · Surprise 60
  AbbVie raised its full-year 2026 revenue and adjusted EPS guidance after reporting Q3 2026 results. The report says the stronger outlook rests on immunology and neuroscience products, including SKYRIZI, RINVOQ, and…
• Quarterly Dividend IncreaseImportance 45 · Surprise 50
  AbbVie approved a 5.2% increase in its quarterly dividend to US$1.82 per share. The increased dividend is scheduled to begin with the February 16, 2027 payment. The report tied the increase to AbbVie's Q3 2026 results…
• Acquisition / Partnership / DivestitureImportance 42 · Surprise 48
  AbbVie acquired Apogee, according to the Q3 key-facts report. The acquisition adds late-stage immunology assets to AbbVie's portfolio. The report did not disclose the transaction value or timing details.
• Competition and Market PositionImportance 38 · Surprise 24
  AbbVie’s immunology products SKYRIZI and RINVOQ were key growth engines in Q3 2026, with reported sales of $5.78 billion and $2.71 billion, respectively. Their growth offset declining sales of the older immunology…
• Net Income and ProfitabilityImportance 21 · Surprise 6
  AbbVie reported Q3 2026 net income of US$4.2 billion. Q3 sales were US$17.4 billion. The report did not provide a year-over-year net income comparison or further details on profitability drivers.

Earnings call · 2026-10-30

• Litigation and Legal RiskImportance 53 · Surprise 60
  AbbVie argued that Botox is excluded from selection under the Inflation Reduction Act because one of its three ingredients is human serum albumin, a protein extracted from human blood plasma. The company said Botox…
• Operating Expense TrendsImportance 50 · Surprise 42
  Third-quarter adjusted R&D expense was 13.9% of sales, while adjusted SG&A expense was 21.2% of sales. For full-year 2026, AbbVie forecast adjusted R&D expense of approximately $9.8 billion and adjusted SG&A expense of…
• Gross Margin DriversImportance 47 · Surprise 6
  Third-quarter adjusted gross margin was 85.1% of sales. AbbVie expects full-year 2026 adjusted gross margin above 84% of sales. Management did not identify a specific year-over-year gross-margin driver in this section.
• Acquisition / Partnership / DivestitureImportance 47 · Surprise 60
  AbbVie completed its acquisition of Apogee Therapeutics during the quarter, adding assets in dermatology, respiratory and related inflammatory diseases. Management characterized the acquired assets as having…
• Quarterly Dividend IncreaseImportance 45 · Surprise 50
  AbbVie announced a 5.2% increase in its quarterly cash dividend to $1.82 per share. The increased dividend begins with the payment payable in February 2027. Management said strong free cash flow supports the dividend…
• Competition and Market PositionImportance 43 · Surprise 32
  Oncology revenues grew 0.9% operationally; Venclexta sales rose 10.7%, supported particularly by CLL and combination use with BTK inhibitors as a preferred fixed-duration treatment globally. Elahere and Epkinly also…
• Aesthetic Care Demand TrendsImportance 43 · Surprise 32
  Aesthetics sales were nearly $1.2 billion, down 1.8% operationally; Botox Cosmetic grew 4.1%, while Juvéderm declined 11.8% amid continued weakness in key dermal-filler markets. Management said economic uncertainty and…
• FX / Currency HeadwindsImportance 41 · Surprise 32
  Foreign exchange reduced third-quarter 2026 operational revenue growth by 0.2%. For full-year sales growth, AbbVie continued to expect an approximately 0.5% favorable FX impact at current rates. The company forecast a…
• Product Launch and TransitionImportance 40 · Surprise 42
  AbbVie launched Skyrizi subcutaneous induction dosing for Crohn's disease, using the same on-body injector as its IBD maintenance dose; gastroenterologists and patients gave favorable feedback on ease of use, speed and…
• Juvmo Parkinson’s Market LaunchImportance 40 · Surprise 42
  AbbVie began launching Juvmo, an FDA-approved Parkinson's treatment that selectively activates D1/D5 dopamine receptors and can be used alone or added to standard care. Management described its motor-control profile…
• Tavapadon Launch DemandImportance 34 · Surprise 42
  Management reported strongly positive initial market feedback for tavapadon, launched only a few weeks earlier, and said demand in the funnel exceeded initial expectations. Physicians responded to trial results showing…
• Geographic Market CommentaryImportance 26 · Surprise 24
  Management said the Boey commercial rollout was underway in Europe and Canada, with high patient satisfaction reported in those markets. TrenibotE had European and Canadian approvals, while AbbVie planned submissions…
• Payer Access and ReimbursementImportance 26 · Surprise 24
  Management said it was beginning to close arrangements with large PBMs and payers and anticipated very strong access for its portfolio, citing physician demand and product profiles. For immunology, it described…
• Rinvoq Dermatology Market ExpansionImportance 26 · Surprise 24
  AbbVie expects Rinvoq to help build the alopecia areata and vitiligo markets, which management said currently generate sales in the small hundreds of millions of dollars despite high prevalence. Management described…
• Regulatory EnvironmentImportance 23 · Surprise 24
  CEO Rob Michael said AbbVie supports the original purpose of the U.S. 340B program but believes its broad patient definition has enabled abuse and increased healthcare costs for employers, taxpayers and patients. He…
• Obesity Portfolio StrategyImportance 23 · Surprise 24
  AbbVie is interested in expanding its obesity portfolio with differentiated assets that could complement its asset 295, including co-formulations in the incretin class or other mechanisms. Management emphasized…
• Rinvoq Hidradenitis Suppurativa PositioningImportance 23 · Surprise 24
  AbbVie expects Rinvoq Phase III results in hidradenitis suppurativa later this year, with HiSCR 50 as the primary endpoint, and will evaluate pain relief, quality of life and flare reduction alongside the primary…
• Macroeconomic Consumer PressureImportance 16 · Surprise 24
  Management said economic uncertainty and lower consumer confidence had pressured the aesthetics category over the preceding several quarters. AbbVie reported early signs of stability and identified the rollout of Boey,…
• Income Tax Rate ChangesImportance 6 · Surprise 6
  AbbVie reported a third-quarter 2026 adjusted tax rate of 13.6%. Management did not provide a prior-year comparison or quantify a tax-rate impact on earnings in this discussion.